Published: June 19th 2024 | Updated: June 24th 2024
Utilizing Biomarkers to Develop First-in-Class Antibody Drug Conjugates to Treat Advanced Solid Tumors
Published: November 8th 2024 | Updated: November 11th 2024
Key Findings of the NIAGARA and HIMALAYA Trials
Published: November 8th 2024 | Updated: November 11th 2024
Johnson & Johnson Submits Regulatory Applications for Darzalex Faspro for High-Risk Smoldering Multiple Myeloma
Published: October 31st 2024 | Updated: November 11th 2024
Expanded Access Treatment Options: Q&A with Johnson & Johnson Innovative Medicine’s Christine MacCracken
Published: October 2nd 2024 | Updated: November 11th 2024
Unlocking value and cost savings in patient services with technology and talent
Published: October 8th 2024 | Updated: November 11th 2024
Are You Up to Date With the Latest FDA Guidance?